Invesco’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $799K | Sell |
512,426
-82,457
| -14% | -$120K | ﹤0.01% | 2966 |
|
|
2025
Q4 | $684K | Buy |
594,883
+73,480
| +14% | +$101K | ﹤0.01% | 3073 |
|
|
2025
Q3 | $704K | Buy |
521,403
+100,703
| +24% | +$114K | ﹤0.01% | 3091 |
|
|
2025
Q2 | $398K | Buy |
420,700
+134,941
| +47% | +$87.4K | ﹤0.01% | 3265 |
|
|
2025
Q1 | $132K | Buy |
285,759
+181,265
| +173% | +$114K | ﹤0.01% | 3594 |
|
|
2024
Q4 | $77.2K | Buy |
104,494
+39,420
| +61% | +$47.5K | ﹤0.01% | 3657 |
|
|
2024
Q3 | $102K | Buy |
65,074
+5,331
| +9% | +$9.49K | ﹤0.01% | 3621 |
|
|
2024
Q2 | $100K | Buy |
59,743
+9,925
| +20% | +$17.8K | ﹤0.01% | 3752 |
|
|
2024
Q1 | $120K | Sell |
49,818
-11,364
| -19% | -$24.4K | ﹤0.01% | 3724 |
|
|
2023
Q4 | $93.6K | Buy |
61,182
+9,245
| +18% | +$11K | ﹤0.01% | 3695 |
|
|
2023
Q3 | $56.6K | Buy |
51,937
+11,820
| +29% | +$20.7K | ﹤0.01% | 3786 |
|
|
2023
Q2 | $91.9K | Sell |
40,117
-855
| -2% | -$2.27K | ﹤0.01% | 3742 |
|
|
2023
Q1 | $99.6K | Sell |
40,972
-251
| -0.6% | -$575 | ﹤0.01% | 3704 |
|
|
2022
Q4 | $78.7K | Buy |
41,223
+9,870
| +31% | +$21K | ﹤0.01% | 3860 |
|
|
2022
Q3 | $75K | Buy |
31,353
+2,830
| +10% | +$7.83K | ﹤0.01% | 3876 |
|
|
2022
Q2 | $53K | Sell |
28,523
-1,326
| -4% | -$2.53K | ﹤0.01% | 3961 |
|
|
2022
Q1 | $62K | Buy |
29,849
+1,071
| +4% | +$2.97K | ﹤0.01% | 3909 |
|
|
2021
Q4 | $113K | Buy |
28,778
+1,025
| +4% | +$4.98K | ﹤0.01% | 3884 |
|
|
2021
Q3 | $133K | Buy |
27,753
+4,568
| +20% | +$18.7K | ﹤0.01% | 3890 |
|
|
2021
Q2 | $106K | Buy |
23,185
+10,714
| +86% | +$51.6K | ﹤0.01% | 3885 |
|
|
2021
Q1 | $73K | Sell |
12,471
-20,353
| -62% | -$141K | ﹤0.01% | 3798 |
|
|
2020
Q4 | $112K | Buy |
32,824
+9,298
| +40% | +$17.7K | ﹤0.01% | 3627 |
|
|
2020
Q3 | $33K | Buy |
23,526
+91
| +0.4% | +$162 | ﹤0.01% | 3610 |
|
|
2020
Q2 | $47K | Buy |
+23,435
| New | +$45.9K | ﹤0.01% | 3619 |
|
|
2019
Q2 | – | Sell |
-34,338
| Closed | -$191K | – | 3750 |
|
|
2019
Q1 | $191K | Buy |
34,338
+2,077
| +6% | +$12.6K | ﹤0.01% | 3629 |
|
|
2018
Q4 | $214K | Sell |
32,261
-6,406
| -17% | -$51.9K | ﹤0.01% | 3541 |
|
|
2018
Q3 | $413K | Buy |
38,667
+9,885
| +34% | +$113K | ﹤0.01% | 3513 |
|
|
2018
Q2 | $345K | Buy |
28,782
+14,916
| +108% | +$153K | ﹤0.01% | 3549 |
|
|
2018
Q1 | $119K | Buy |
13,866
+1,685
| +14% | +$15.6K | ﹤0.01% | 3660 |
|
|
2017
Q4 | $120K | Buy |
12,181
+227
| +2% | +$2.36K | ﹤0.01% | 3598 |
|
|
2017
Q3 | $147K | Buy |
11,954
+694
| +6% | +$10.2K | ﹤0.01% | 3587 |
|
|
2017
Q2 | $185K | Sell |
11,260
-415,274
| -97% | -$6.43M | ﹤0.01% | 3599 |
|
|
2017
Q1 | $6.12M | Sell |
426,534
-82,056
| -16% | -$1.22M | ﹤0.01% | 1856 |
|
|
2016
Q4 | $7.03M | Sell |
508,590
-106,016
| -17% | -$1.7M | ﹤0.01% | 1761 |
|
|
2016
Q3 | $11.1M | Sell |
614,606
-1,672
| -0.3% | -$26.9K | ﹤0.01% | 1433 |
|
|
2016
Q2 | $8.84M | Sell |
616,278
-154,092
| -20% | -$2.09M | ﹤0.01% | 1508 |
|
|
2016
Q1 | $9.21M | Buy |
770,370
+639,661
| +489% | +$6.71M | ﹤0.01% | 1472 |
|
|
2015
Q4 | $1.74M | Sell |
130,709
-1,059
| -0.8% | -$13K | ﹤0.01% | 2622 |
|
|
2015
Q3 | $1.42M | Buy |
131,768
+131,088
| +19,278% | +$1.43M | ﹤0.01% | 2725 |
|
|
2015
Q2 | $5K | Buy |
+680
| New | +$4.99K | ﹤0.01% | 4206 |
|
|
2015
Q1 | – | Sell |
-54,287
| Closed | -$346K | – | 4044 |
|
|
2014
Q4 | $346K | Buy |
54,287
+1,293
| +2% | +$10.4K | ﹤0.01% | 3456 |
|
|
2014
Q3 | $523K | Sell |
52,994
-1,874
| -3% | -$20K | ﹤0.01% | 3299 |
|
|
2014
Q2 | $618K | Buy |
54,868
+1,656
| +3% | +$17.8K | ﹤0.01% | 3259 |
|
|
2014
Q1 | $644K | Sell |
53,212
-14,884
| -22% | -$190K | ﹤0.01% | 3284 |
|
|
2013
Q4 | $857K | Buy |
68,096
+13
| +0% | +$207 | ﹤0.01% | 3185 |
|
|
2013
Q3 | $1.13M | Hold |
68,083
| – | – | ﹤0.01% | 2938 |
|
|
2013
Q2 | $1.03M | Buy |
+68,083
| New | +$1.03M | ﹤0.01% | 2844 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Invesco's LXRX Position: Q1 2026 in Review
Invesco reduced its Lexicon Pharmaceuticals (LXRX) stake by 14% in Q1 2026, selling an estimated $120K and leaving 512,426 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.
Invesco first reported a position in LXRX in Q2 2013 and has held it in 47 quarters since. The position peaked at $11.1M in Q3 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Invesco held 512,426 shares of Lexicon Pharmaceuticals worth $799K as of Q1 2026.
- Invesco sold 82,457 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $120K.
- Lexicon Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2966 holding.
- Invesco first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Invesco's Lexicon Pharmaceuticals position peaked at $11.1M in Q3 2016.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.